Skip to main content
Premium Trial:

Request an Annual Quote

Cellular Dynamics Nets $43M in IPO

NEW YORK (GenomeWeb News) – Cellular Dynamics International said on Tuesday that it has closed its initial public offering, raising net proceeds of about $43 million.

The Madison, Wis.-based stem cell technologies firm, which went public last week, said it completed its offering of more than 3.8 million shares of common stock at $12.00 per share. The company trades on the Nasdaq under ticker symbol "ICEL".

CDI has offered its underwriters on the offering a 30-day option to purchase up to an additional 576,900 shares of its stock. JP Morgan Securities was the sole book-running agent, while Cowen & Co. and Leerink Swann were co-managers on the offering.

Proceeds from the offering will go toward research and product development work; sales and marketing activities, including expanding the firm's sales force, property, plant, and equipment; working capital; and other general corporate purposes.

CDI filed to go public in June.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.